Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8908 |
High Similarity |
NPD4940 |
Approved |
0.8596 |
High Similarity |
NPD5016 |
Approved |
0.8251 |
Intermediate Similarity |
NPD1896 |
Approved |
0.8118 |
Intermediate Similarity |
NPD1871 |
Approved |
0.8075 |
Intermediate Similarity |
NPD1952 |
Discontinued |
0.7958 |
Intermediate Similarity |
NPD2879 |
Approved |
0.7958 |
Intermediate Similarity |
NPD2881 |
Approved |
0.7903 |
Intermediate Similarity |
NPD1658 |
Discontinued |
0.7868 |
Intermediate Similarity |
NPD2411 |
Approved |
0.7841 |
Intermediate Similarity |
NPD509 |
Phase 3 |
0.7835 |
Intermediate Similarity |
NPD2008 |
Discontinued |
0.7795 |
Intermediate Similarity |
NPD3905 |
Phase 3 |
0.7722 |
Intermediate Similarity |
NPD5996 |
Clinical (unspecified phase) |
0.7697 |
Intermediate Similarity |
NPD4213 |
Clinical (unspecified phase) |
0.764 |
Intermediate Similarity |
NPD3889 |
Approved |
0.7632 |
Intermediate Similarity |
NPD460 |
Discontinued |
0.7626 |
Intermediate Similarity |
NPD1600 |
Suspended |
0.7576 |
Intermediate Similarity |
NPD2442 |
Approved |
0.7576 |
Intermediate Similarity |
NPD2443 |
Approved |
0.7541 |
Intermediate Similarity |
NPD5943 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6794 |
Approved |
0.743 |
Intermediate Similarity |
NPD2149 |
Clinical (unspecified phase) |
0.7429 |
Intermediate Similarity |
NPD2128 |
Phase 1 |
0.7427 |
Intermediate Similarity |
NPD6210 |
Phase 3 |
0.7418 |
Intermediate Similarity |
NPD6142 |
Phase 3 |
0.7411 |
Intermediate Similarity |
NPD4924 |
Clinical (unspecified phase) |
0.7396 |
Intermediate Similarity |
NPD3431 |
Approved |
0.7396 |
Intermediate Similarity |
NPD3430 |
Approved |
0.7363 |
Intermediate Similarity |
NPD2408 |
Discontinued |
0.735 |
Intermediate Similarity |
NPD6328 |
Clinical (unspecified phase) |
0.7337 |
Intermediate Similarity |
NPD7103 |
Approved |
0.733 |
Intermediate Similarity |
NPD2524 |
Discontinued |
0.7315 |
Intermediate Similarity |
NPD4938 |
Phase 2 |
0.7306 |
Intermediate Similarity |
NPD3959 |
Phase 2 |
0.7306 |
Intermediate Similarity |
NPD3962 |
Phase 2 |
0.7297 |
Intermediate Similarity |
NPD7006 |
Approved |
0.7291 |
Intermediate Similarity |
NPD4863 |
Approved |
0.7277 |
Intermediate Similarity |
NPD3246 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD5001 |
Clinical (unspecified phase) |
0.7264 |
Intermediate Similarity |
NPD3839 |
Phase 2 |
0.7264 |
Intermediate Similarity |
NPD7767 |
Approved |
0.7264 |
Intermediate Similarity |
NPD3840 |
Phase 2 |
0.7245 |
Intermediate Similarity |
NPD2880 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD5072 |
Discontinued |
0.7234 |
Intermediate Similarity |
NPD717 |
Approved |
0.7225 |
Intermediate Similarity |
NPD2591 |
Phase 2 |
0.722 |
Intermediate Similarity |
NPD2363 |
Discontinued |
0.7215 |
Intermediate Similarity |
NPD5821 |
Approved |
0.7211 |
Intermediate Similarity |
NPD721 |
Approved |
0.7207 |
Intermediate Similarity |
NPD2927 |
Phase 3 |
0.7188 |
Intermediate Similarity |
NPD2009 |
Clinical (unspecified phase) |
0.7186 |
Intermediate Similarity |
NPD6837 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD5730 |
Phase 2 |
0.7181 |
Intermediate Similarity |
NPD40 |
Phase 2 |
0.7171 |
Intermediate Similarity |
NPD7657 |
Approved |
0.7171 |
Intermediate Similarity |
NPD7656 |
Approved |
0.7164 |
Intermediate Similarity |
NPD6229 |
Phase 2 |
0.7163 |
Intermediate Similarity |
NPD4541 |
Clinical (unspecified phase) |
0.7151 |
Intermediate Similarity |
NPD966 |
Clinical (unspecified phase) |
0.715 |
Intermediate Similarity |
NPD2412 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7232 |
Discontinued |
0.7128 |
Intermediate Similarity |
NPD1272 |
Clinical (unspecified phase) |
0.7121 |
Intermediate Similarity |
NPD6469 |
Phase 3 |
0.7121 |
Intermediate Similarity |
NPD6468 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD1591 |
Approved |
0.7103 |
Intermediate Similarity |
NPD7887 |
Approved |
0.7103 |
Intermediate Similarity |
NPD7888 |
Approved |
0.7098 |
Intermediate Similarity |
NPD4988 |
Discontinued |
0.7097 |
Intermediate Similarity |
NPD3347 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD6579 |
Phase 2 |
0.7092 |
Intermediate Similarity |
NPD3403 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD1037 |
Clinical (unspecified phase) |
0.7056 |
Intermediate Similarity |
NPD7694 |
Discontinued |
0.7056 |
Intermediate Similarity |
NPD7406 |
Phase 2 |
0.7053 |
Intermediate Similarity |
NPD702 |
Clinical (unspecified phase) |
0.7052 |
Intermediate Similarity |
NPD569 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD4902 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD7568 |
Phase 1 |
0.7044 |
Intermediate Similarity |
NPD6271 |
Approved |
0.7037 |
Intermediate Similarity |
NPD4155 |
Approved |
0.7027 |
Intermediate Similarity |
NPD1215 |
Discontinued |
0.702 |
Intermediate Similarity |
NPD7023 |
Clinical (unspecified phase) |
0.7014 |
Intermediate Similarity |
NPD5827 |
Discontinued |
0.6995 |
Remote Similarity |
NPD4299 |
Phase 1 |
0.6995 |
Remote Similarity |
NPD5000 |
Phase 2 |
0.6995 |
Remote Similarity |
NPD4446 |
Approved |
0.6978 |
Remote Similarity |
NPD7398 |
Approved |
0.6978 |
Remote Similarity |
NPD7397 |
Approved |
0.6973 |
Remote Similarity |
NPD1313 |
Approved |
0.6965 |
Remote Similarity |
NPD8248 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6619 |
Phase 3 |
0.695 |
Remote Similarity |
NPD5467 |
Phase 2 |
0.6944 |
Remote Similarity |
NPD2660 |
Approved |
0.6944 |
Remote Similarity |
NPD2662 |
Approved |
0.6935 |
Remote Similarity |
NPD2392 |
Clinical (unspecified phase) |
0.6935 |
Remote Similarity |
NPD3361 |
Phase 1 |
0.6932 |
Remote Similarity |
NPD4047 |
Discontinued |
0.6932 |
Remote Similarity |
NPD9724 |
Phase 1 |
0.6931 |
Remote Similarity |
NPD7297 |
Phase 2 |
0.693 |
Remote Similarity |
NPD5887 |
Clinical (unspecified phase) |
0.6927 |
Remote Similarity |
NPD1506 |
Discontinued |
0.6927 |
Remote Similarity |
NPD4011 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD2770 |
Discontinued |
0.6919 |
Remote Similarity |
NPD3485 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD6470 |
Phase 3 |
0.6911 |
Remote Similarity |
NPD3432 |
Approved |
0.69 |
Remote Similarity |
NPD5446 |
Phase 2 |
0.6893 |
Remote Similarity |
NPD6521 |
Phase 3 |
0.6893 |
Remote Similarity |
NPD6486 |
Approved |
0.6893 |
Remote Similarity |
NPD6487 |
Approved |
0.6893 |
Remote Similarity |
NPD6520 |
Phase 3 |
0.6891 |
Remote Similarity |
NPD2138 |
Approved |
0.6891 |
Remote Similarity |
NPD2137 |
Approved |
0.6891 |
Remote Similarity |
NPD4441 |
Phase 2 |
0.6889 |
Remote Similarity |
NPD5807 |
Phase 2 |
0.6878 |
Remote Similarity |
NPD6403 |
Clinical (unspecified phase) |
0.6862 |
Remote Similarity |
NPD2875 |
Clinical (unspecified phase) |
0.6858 |
Remote Similarity |
NPD7996 |
Phase 2 |
0.6853 |
Remote Similarity |
NPD1043 |
Phase 3 |
0.6853 |
Remote Similarity |
NPD3870 |
Clinical (unspecified phase) |
0.6853 |
Remote Similarity |
NPD3871 |
Clinical (unspecified phase) |
0.684 |
Remote Similarity |
NPD7776 |
Approved |
0.6837 |
Remote Similarity |
NPD3002 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD5012 |
Phase 2 |
0.6821 |
Remote Similarity |
NPD1308 |
Approved |
0.6814 |
Remote Similarity |
NPD3774 |
Approved |
0.6814 |
Remote Similarity |
NPD2807 |
Discontinued |
0.6814 |
Remote Similarity |
NPD3775 |
Approved |
0.6814 |
Remote Similarity |
NPD3773 |
Approved |
0.681 |
Remote Similarity |
NPD7557 |
Clinical (unspecified phase) |
0.6809 |
Remote Similarity |
NPD1292 |
Clinical (unspecified phase) |
0.6808 |
Remote Similarity |
NPD5199 |
Approved |
0.6808 |
Remote Similarity |
NPD5198 |
Approved |
0.6804 |
Remote Similarity |
NPD2111 |
Clinical (unspecified phase) |
0.6804 |
Remote Similarity |
NPD3512 |
Clinical (unspecified phase) |
0.6792 |
Remote Similarity |
NPD3805 |
Clinical (unspecified phase) |
0.6792 |
Remote Similarity |
NPD6218 |
Discontinued |
0.6789 |
Remote Similarity |
NPD1580 |
Clinical (unspecified phase) |
0.6786 |
Remote Similarity |
NPD3315 |
Phase 3 |
0.6786 |
Remote Similarity |
NPD2793 |
Discontinued |
0.6786 |
Remote Similarity |
NPD6721 |
Phase 1 |
0.6784 |
Remote Similarity |
NPD1919 |
Approved |
0.6784 |
Remote Similarity |
NPD1920 |
Approved |
0.6779 |
Remote Similarity |
NPD2819 |
Clinical (unspecified phase) |
0.6771 |
Remote Similarity |
NPD3041 |
Approved |
0.6766 |
Remote Similarity |
NPD3362 |
Clinical (unspecified phase) |
0.6766 |
Remote Similarity |
NPD4848 |
Phase 1 |
0.6758 |
Remote Similarity |
NPD2400 |
Phase 2 |
0.6753 |
Remote Similarity |
NPD4649 |
Clinical (unspecified phase) |
0.6748 |
Remote Similarity |
NPD7208 |
Approved |
0.6748 |
Remote Similarity |
NPD5425 |
Phase 1 |
0.6748 |
Remote Similarity |
NPD7209 |
Approved |
0.6748 |
Remote Similarity |
NPD7207 |
Approved |
0.6738 |
Remote Similarity |
NPD1631 |
Approved |
0.672 |
Remote Similarity |
NPD2333 |
Discontinued |
0.672 |
Remote Similarity |
NPD2390 |
Clinical (unspecified phase) |
0.6719 |
Remote Similarity |
NPD2406 |
Clinical (unspecified phase) |
0.6716 |
Remote Similarity |
NPD1838 |
Clinical (unspecified phase) |
0.6715 |
Remote Similarity |
NPD7323 |
Phase 2 |
0.6714 |
Remote Similarity |
NPD2812 |
Clinical (unspecified phase) |
0.6714 |
Remote Similarity |
NPD2813 |
Phase 3 |
0.6712 |
Remote Similarity |
NPD1579 |
Discontinued |
0.6704 |
Remote Similarity |
NPD6017 |
Discontinued |
0.6702 |
Remote Similarity |
NPD5269 |
Clinical (unspecified phase) |
0.6702 |
Remote Similarity |
NPD4524 |
Discontinued |
0.67 |
Remote Similarity |
NPD6577 |
Clinical (unspecified phase) |
0.67 |
Remote Similarity |
NPD5885 |
Approved |
0.6696 |
Remote Similarity |
NPD3360 |
Clinical (unspecified phase) |
0.6684 |
Remote Similarity |
NPD3607 |
Clinical (unspecified phase) |
0.6683 |
Remote Similarity |
NPD6145 |
Phase 1 |
0.6682 |
Remote Similarity |
NPD5533 |
Discontinued |
0.6667 |
Remote Similarity |
NPD3248 |
Phase 1 |
0.6667 |
Remote Similarity |
NPD2004 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD8050 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD4736 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD1630 |
Approved |
0.6651 |
Remote Similarity |
NPD4882 |
Clinical (unspecified phase) |
0.6651 |
Remote Similarity |
NPD4341 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD1541 |
Approved |
0.6636 |
Remote Similarity |
NPD5907 |
Phase 3 |
0.6633 |
Remote Similarity |
NPD7884 |
Discontinued |
0.663 |
Remote Similarity |
NPD737 |
Phase 2 |
0.6619 |
Remote Similarity |
NPD2295 |
Clinical (unspecified phase) |
0.6618 |
Remote Similarity |
NPD1982 |
Phase 1 |
0.6618 |
Remote Similarity |
NPD2947 |
Clinical (unspecified phase) |
0.6618 |
Remote Similarity |
NPD4364 |
Phase 1 |
0.6616 |
Remote Similarity |
NPD3378 |
Clinical (unspecified phase) |
0.6615 |
Remote Similarity |
NPD2481 |
Approved |
0.6615 |
Remote Similarity |
NPD5473 |
Discontinued |
0.6615 |
Remote Similarity |
NPD2479 |
Phase 3 |
0.6614 |
Remote Similarity |
NPD4550 |
Clinical (unspecified phase) |
0.6614 |
Remote Similarity |
NPD2915 |
Discontinued |
0.6608 |
Remote Similarity |
NPD7860 |
Clinical (unspecified phase) |
0.6604 |
Remote Similarity |
NPD2794 |
Discontinued |
0.6603 |
Remote Similarity |
NPD6135 |
Phase 1 |
0.6602 |
Remote Similarity |
NPD3891 |
Phase 2 |
0.6602 |
Remote Similarity |
NPD7817 |
Phase 1 |
0.6602 |
Remote Similarity |
NPD3890 |
Phase 2 |
0.66 |
Remote Similarity |
NPD2324 |
Approved |
0.66
|
Remote Similarity |
NPD5685 |
Approved |